Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial

The Lancet ◽  
2006 ◽  
Vol 368 (9552) ◽  
pp. 2053-2060 ◽  
Author(s):  
Sue M Moss ◽  
Howard Cuckle ◽  
Andy Evans ◽  
Louise Johns ◽  
Michael Waller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomised Controlled Trial ◽  
Cancer Mortality ◽  
Controlled Trial ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Randomised Controlled

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

The Lancet ◽  
2007 ◽  
Vol 369 (9555) ◽  
pp. 29-36 ◽  
Author(s):  
Ian Smith ◽  
Marion Procter ◽  
Richard D Gelber ◽  
Sébastien Guillaume ◽  
Andrea Feyereislova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Randomised Controlled ◽  
Positive Breast Cancer

scholarly journals Mammography Screening: Keeping Women Alive

2011 ◽  
Vol 7 (6) ◽  
pp. 631-633 ◽  
Author(s):  
André LM Verbeek
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Interval Cancer ◽  
Positive Outcome ◽  
Mammographic Screening ◽  
Breast Cancer Death ◽  
Human Cost ◽  
The Uk

Evaluation of: Tabár L, Vitak B, Chen TH et al. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260(3), 658–663 (2011). In the 1980s, the periodic invitation of women aged 40–69 years for mammographic screening in the Swedish Two-County Trial showed a strong 30% reduction in breast cancer mortality. The result of 2–3-yearly mammographic examinations has persisted throughout the long follow-up of three decades. Through the richness of the collected and verified data, the trial has also demonstrated a substantial and absolute reduction in mortality risk. For each 414 women screened for 7 years (approximately four screening examinations), one breast cancer death was prevented. Transferring these outcomes to, for example, the national program of the UK, for every 1000 women aged 47–73 years attending the 3-yearly screenings (nine screening examinations) at least five to seven breast cancer deaths would be prevented. In recent follow-up papers by the Swedish trial group, the major human cost of screening (false-positive outcome, occurrence of interval cancer, overdiagnosis and radiation exposure) were judged to be in balance with the accurately demonstrated mortality benefit.

Sign in / Sign up

Export Citation Format

Share Document